APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Neoplastic Pharmaceutical Agent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Neoplastic Pharmaceutical Agent Market Outlook and Growth Opportunities 2026

23 December 2025201 pages

Choose your research edition.

Industry ResearchAnti-Neoplastic Pharmaceutical Agent Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Neoplastic Pharmaceutical Agent Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Anti-Neoplastic Pharmaceutical Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Neoplastic Pharmaceutical Agent Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Neoplastic Pharmaceutical Agent Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Anti-Neoplastic Pharmaceutical Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Neoplastic Pharmaceutical Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Neoplastic Pharmaceutical Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Neoplastic Pharmaceutical Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Neoplastic Pharmaceutical Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Neoplastic Pharmaceutical Agent market include Innovent, Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer and Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anti-Neoplastic Pharmaceutical Agent market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Neoplastic Pharmaceutical Agent and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Neoplastic Pharmaceutical Agent revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-Neoplastic Pharmaceutical Agent market.

Anti-Neoplastic Pharmaceutical Agent Segment by Company

Innovent

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

Hengrui Medicine

GSK

Bristol-Myers Squibb

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Gilead Sciences

Exelixis

Anti-Neoplastic Pharmaceutical Agent Segment by Type

Cancer Immunotherapy

Chemotherapy

Targeted Therapy

Other

Anti-Neoplastic Pharmaceutical Agent Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Anti-Neoplastic Pharmaceutical Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Neoplastic Pharmaceutical Agent status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anti-Neoplastic Pharmaceutical Agent key companies, revenue, market share, and recent developments.

3. To split the Anti-Neoplastic Pharmaceutical Agent breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anti-Neoplastic Pharmaceutical Agent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Neoplastic Pharmaceutical Agent significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Neoplastic Pharmaceutical Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Neoplastic Pharmaceutical Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Neoplastic Pharmaceutical Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Neoplastic Pharmaceutical Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Neoplastic Pharmaceutical Agent industry.

Chapter 3: Detailed analysis of Anti-Neoplastic Pharmaceutical Agent company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anti-Neoplastic Pharmaceutical Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anti-Neoplastic Pharmaceutical Agent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Neoplastic Pharmaceutical Agent Industry Trends Table 2. Anti-Neoplastic Pharmaceutical Agent Industry Drivers Table 3. Anti-Neoplastic Pharmaceutical Agent Industry Opportunities and Challenges Table 4. Anti-Neoplastic Pharmaceutical Agent Industry Restraints Table 5. Global Anti-Neoplastic Pharmaceutical Agent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Neoplastic Pharmaceutical Agent Revenue Share by Company (2021-2026) Table 7. Global Anti-Neoplastic Pharmaceutical Agent Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anti-Neoplastic Pharmaceutical Agent Key Company Manufacturing Base & Headquarters Table 9. Global Anti-Neoplastic Pharmaceutical Agent Company, Product Type & Application Table 10. Global Anti-Neoplastic Pharmaceutical Agent Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anti-Neoplastic Pharmaceutical Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cancer Immunotherapy Table 15. Significant Companies of Chemotherapy Table 16. Significant Companies of Targeted Therapy Table 17. Significant Companies of Other Table 18. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type (2021-2026) Table 22. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Blood-related Cancer Table 24. Significant Companies of Breast Cancer Table 25. Significant Companies of Prostate Cancer Table 26. Significant Companies of Lung Cancer Table 27. Significant Companies of Other Table 28. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application (2021-2026) Table 32. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application (2027-2032) Table 33. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Region (2021-2026) Table 36. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Region (2027-2032) Table 38. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Market Share by Country (2021-2026) Table 41. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Market Share by Country (2027-2032) Table 43. Innovent Company Information Table 44. Innovent Business Overview Table 45. Innovent Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Innovent Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 47. Innovent Recent Development Table 48. Takeda Company Information Table 49. Takeda Business Overview Table 50. Takeda Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Takeda Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 52. Takeda Recent Development Table 53. Johnson & Johnson Company Information Table 54. Johnson & Johnson Business Overview Table 55. Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 57. Johnson & Johnson Recent Development Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Novartis Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 62. Novartis Recent Development Table 63. Merck KGaA Company Information Table 64. Merck KGaA Business Overview Table 65. Merck KGaA Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Merck KGaA Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 67. Merck KGaA Recent Development Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Roche Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 72. Roche Recent Development Table 73. Eli Lilly Company Information Table 74. Eli Lilly Business Overview Table 75. Eli Lilly Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Eli Lilly Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 77. Eli Lilly Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pfizer Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 82. Pfizer Recent Development Table 83. Hengrui Medicine Company Information Table 84. Hengrui Medicine Business Overview Table 85. Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 87. Hengrui Medicine Recent Development Table 88. GSK Company Information Table 89. GSK Business Overview Table 90. GSK Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GSK Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 92. GSK Recent Development Table 93. Bristol-Myers Squibb Company Information Table 94. Bristol-Myers Squibb Business Overview Table 95. Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 97. Bristol-Myers Squibb Recent Development Table 98. Amgen Company Information Table 99. Amgen Business Overview Table 100. Amgen Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Amgen Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 102. Amgen Recent Development Table 103. AbbVie Company Information Table 104. AbbVie Business Overview Table 105. AbbVie Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. AbbVie Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 107. AbbVie Recent Development Table 108. AstraZeneca Company Information Table 109. AstraZeneca Business Overview Table 110. AstraZeneca Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. AstraZeneca Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 112. AstraZeneca Recent Development Table 113. Seagen Company Information Table 114. Seagen Business Overview Table 115. Seagen Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Seagen Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 117. Seagen Recent Development Table 118. Regeneron Company Information Table 119. Regeneron Business Overview Table 120. Regeneron Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Regeneron Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 122. Regeneron Recent Development Table 123. Ono Pharmaceutical Company Information Table 124. Ono Pharmaceutical Business Overview Table 125. Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 127. Ono Pharmaceutical Recent Development Table 128. Merck & Co Company Information Table 129. Merck & Co Business Overview Table 130. Merck & Co Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Merck & Co Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 132. Merck & Co Recent Development Table 133. Gilead Sciences Company Information Table 134. Gilead Sciences Business Overview Table 135. Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 137. Gilead Sciences Recent Development Table 138. Exelixis Company Information Table 139. Exelixis Business Overview Table 140. Exelixis Anti-Neoplastic Pharmaceutical Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Exelixis Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 142. Exelixis Recent Development Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Anti-Neoplastic Pharmaceutical Agent Product Image Figure 2. Global Anti-Neoplastic Pharmaceutical Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Neoplastic Pharmaceutical Agent Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cancer Immunotherapy Image Figure 8. Chemotherapy Image Figure 9. Targeted Therapy Image Figure 10. Other Image Figure 11. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type (2021-2032) Figure 14. Blood-related Cancer Image Figure 15. Breast Cancer Image Figure 16. Prostate Cancer Image Figure 17. Lung Cancer Image Figure 18. Other Image Figure 19. Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application (2021-2032) Figure 22. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032) & (US$ Million) Figure 25. North America Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032) & (US$ Million) Figure 31. South America Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Cancer Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Innovent
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • Hengrui Medicine
  • GSK
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Gilead Sciences
  • Exelixis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-Neoplastic Pharmaceutical Agent Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anti-Neoplastic Pharmaceutical Agent Market Dynamics
  1. 2.1 Anti-Neoplastic Pharmaceutical Agent Industry Trends
  2. 2.2 Anti-Neoplastic Pharmaceutical Agent Industry Drivers
  3. 2.3 Anti-Neoplastic Pharmaceutical Agent Industry Opportunities and Challenges
  4. 2.4 Anti-Neoplastic Pharmaceutical Agent Industry Restraints
3 Anti-Neoplastic Pharmaceutical Agent Market by Company
  1. 3.1 Global Anti-Neoplastic Pharmaceutical Agent Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Neoplastic Pharmaceutical Agent Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Neoplastic Pharmaceutical Agent Company Ranking (2024-2026)
  4. 3.4 Global Anti-Neoplastic Pharmaceutical Agent Company Manufacturing Base and Headquarters
  5. 3.5 Global Anti-Neoplastic Pharmaceutical Agent Company Product Type and Application
  6. 3.6 Global Anti-Neoplastic Pharmaceutical Agent Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anti-Neoplastic Pharmaceutical Agent Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anti-Neoplastic Pharmaceutical Agent Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anti-Neoplastic Pharmaceutical Agent Market by Type
  1. 4.1 Anti-Neoplastic Pharmaceutical Agent Type Introduction
  2. 4.1.1 Cancer Immunotherapy
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Targeted Therapy
  5. 4.1.4 Other
  6. 4.2 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Type
  7. 4.2.1 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Type (2021-2032)
  9. 4.2.3 Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type (2021-2032)
5 Anti-Neoplastic Pharmaceutical Agent Market by Application
  1. 5.1 Anti-Neoplastic Pharmaceutical Agent Application Introduction
  2. 5.1.1 Blood-related Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Other
  7. 5.2 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Application
  8. 5.2.1 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Application (2021-2032)
  10. 5.2.3 Global Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application (2021-2032)
6 Anti-Neoplastic Pharmaceutical Agent Regional Value Analysis
  1. 6.1 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032)
  7. 6.3.2 North America Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032)
  10. 6.4.2 Europe Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032)
  16. 6.6.2 South America Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Country, 2025 VS 2032
7 Anti-Neoplastic Pharmaceutical Agent Country-level Value Analysis
  1. 7.1 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anti-Neoplastic Pharmaceutical Agent Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anti-Neoplastic Pharmaceutical Agent Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anti-Neoplastic Pharmaceutical Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Innovent
  2. 8.1.1 Innovent Company Information
  3. 8.1.2 Innovent Business Overview
  4. 8.1.3 Innovent Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Innovent Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  6. 8.1.5 Innovent Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck KGaA
  26. 8.5.1 Merck KGaA Company Information
  27. 8.5.2 Merck KGaA Business Overview
  28. 8.5.3 Merck KGaA Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck KGaA Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  30. 8.5.5 Merck KGaA Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Hengrui Medicine
  50. 8.9.1 Hengrui Medicine Company Information
  51. 8.9.2 Hengrui Medicine Business Overview
  52. 8.9.3 Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  54. 8.9.5 Hengrui Medicine Recent Developments
  55. 8.10 GSK
  56. 8.10.1 GSK Company Information
  57. 8.10.2 GSK Business Overview
  58. 8.10.3 GSK Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GSK Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  60. 8.10.5 GSK Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amgen Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  72. 8.12.5 Amgen Recent Developments
  73. 8.13 AbbVie
  74. 8.13.1 AbbVie Company Information
  75. 8.13.2 AbbVie Business Overview
  76. 8.13.3 AbbVie Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AbbVie Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  78. 8.13.5 AbbVie Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Seagen
  86. 8.15.1 Seagen Company Information
  87. 8.15.2 Seagen Business Overview
  88. 8.15.3 Seagen Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Seagen Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  90. 8.15.5 Seagen Recent Developments
  91. 8.16 Regeneron
  92. 8.16.1 Regeneron Company Information
  93. 8.16.2 Regeneron Business Overview
  94. 8.16.3 Regeneron Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Regeneron Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  96. 8.16.5 Regeneron Recent Developments
  97. 8.17 Ono Pharmaceutical
  98. 8.17.1 Ono Pharmaceutical Company Information
  99. 8.17.2 Ono Pharmaceutical Business Overview
  100. 8.17.3 Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  102. 8.17.5 Ono Pharmaceutical Recent Developments
  103. 8.18 Merck & Co
  104. 8.18.1 Merck & Co Company Information
  105. 8.18.2 Merck & Co Business Overview
  106. 8.18.3 Merck & Co Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Merck & Co Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  108. 8.18.5 Merck & Co Recent Developments
  109. 8.19 Gilead Sciences
  110. 8.19.1 Gilead Sciences Company Information
  111. 8.19.2 Gilead Sciences Business Overview
  112. 8.19.3 Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  114. 8.19.5 Gilead Sciences Recent Developments
  115. 8.20 Exelixis
  116. 8.20.1 Exelixis Company Information
  117. 8.20.2 Exelixis Business Overview
  118. 8.20.3 Exelixis Anti-Neoplastic Pharmaceutical Agent Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Exelixis Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  120. 8.20.5 Exelixis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst